Neuromuscular features in Marfan syndrome

Clinical Genetics

Volumn 76, Issue 1, 2009, Pages 25-37

  Voermans, Nicol C ^a   Timmermans, J ^b   Van Alfen, N ^a,b   Pillen, S ^b   Op Den Akker, J ^b   Lammens, M ^a,b   Zwarts, M J ^b   Van Rooij, I A L M ^b   Hamel, B C ^b   Van Engelen, B G ^a  

^a RADBOUD UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Fibrillin; Marfan syndrome; Myopathy; Neurology; Neuromuscular features; Polyneuropathy; Rradiculopathy

Indexed keywords

ADULT; AGE DISTRIBUTION; AGED; ARM MOVEMENT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DURAL ECTASIA; ECHOGRAPHY; ELBOW FLEXION; ELECTROMYOGRAPHY; FEMALE; HUMAN; HYPOREFLEXIA; JOINT FUNCTION; JOINT HYPERMOBILITY; KYPHOSCOLIOSIS; MALE; MARFAN SYNDROME; MENINGEAL CYST; MUSCLE BIOPSY; MUSCLE CONTRACTURE; NERVE CONDUCTION; NEUROIMAGING; NEUROMUSCULAR DISEASE; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PTOSIS; QUESTIONNAIRE; SELF REPORT;

ADULT; AGED; BIOPSY; CASE-CONTROL STUDIES; ELECTROMYOGRAPHY; FEMALE; HUMANS; LUMBAR VERTEBRAE; MALE; MARFAN SYNDROME; MIDDLE AGED; MUSCLE STRENGTH DYNAMOMETER; MUSCLES; NEURAL CONDUCTION; NEUROMUSCULAR DISEASES; PHYSICAL EXAMINATION;

EID: 67650908155     PISSN: 00099163     EISSN: 13990004     Source Type: Journal    
DOI: 10.1111/j.1399-0004.2009.01197.x     Document Type: Article

References (53)

1. Gray JR, Bridges AB, West RR et al. Life expectancy in British Marfan syndrome populations. Clin Genet 1998: 54: 124-128.
2. Loeys B, De Backer J, Van Acker, et al. Comprehensive molecular screening of the FBN1 gene favors locus homogeneity of classical Marfan syndrome. Hum Mutat 2004: 24: 140-146.
3. Silverman DI, Burton KJ, Gray J et al. Life expectancy in the Marfan syndrome. Am J Cardiol 1995: 75: 157-160.
4. von Kodolitsch Y, Robinson P. Marfan syndrome: An update of genetics, medical and surgical management. Heart 2007: 93: 755-760.
5. Dean JC. Marfan syndrome: Clinical diagnosis and management. Eur J Hum Genet 2007: 15: 724-733.
6. Jones KB, Sponseller PD, Erkula G et al. Symposium on the musculoskeletal aspects of Marfan syndrome: Meeting report and state of the science. J Orthop Res 2007: 25: 413-422.
7. Ramirez F, Dietz HC. Marfan syndrome: From molecular pathogenesis to clinical treatment. Curr Opin Genet Dev 2007:17: 252-258.
8. Hasan A, Poloniecki J, Child A. Ageing in Marfan syndrome. Int J Clin Pract 2007: 61: 1308-1320.
9. Marfan AB. Un cas de déformation congénitale des quatres membres, plus prononcée aux extrémités caractérisée par l'allongement des os avec un certain degrée d'amincissement. Bull Mem Soc Med Hop (Paris) 1896: 13: 220-226.
10. Young M. Arachnodactyly. Arch Dis Child 1929: 4: 190-209.
11. Fulcher P, Southworth H. Arachnodactyly and its medical complications. Arch Intern Med 1938: 61: 703-963.
12. Lambie C, Shellshear K, Shellshear J. Arachnodactyly or Marfan's syndrome. Med J Austr 1950: 1: 213-223.
13. Goebel HH, Muller J, DeMyer W. Myopathy associated with Marfan's syndrome. Fine structural and histochemical observations. Neurology 1973: 23: 1257-1268.
14. Barrison IG, Isenberg DA, Kane SP. Arachnodactyly with unusual neuromyopathic and skeletal abnormalities. J R Soc Med 1980: 73: 64-68.
15. Jadro-Santel D, Grcevic N, Dogan S, Franjic J, Benc H. Centronuclear myopathy with type I fibre hypotrophy and "fingerprint"inclusions associated with Marfan's syndrome. J Neurol Sci 1980: 45: 43-56.
16. Pages M, Cesari JB, Pages AM. [Centronuclear myopathy. Complete review of the literature apropos of a case]. Ann Pathol 1982: 2: 301-310.
17. De Paepe A, Devereux R, Dietz H, Hennekam R, Pyeritz R. Revised diagnostic criteria for the Marfan syndrome. Am J Med Genet 1996: 62: 417-426.
18. Lampe AK, Bushby KM. Collagen VI related muscle disorders. J Med Genet 2005: 42: 673-685.
19. Voermans NC, Bonnemann CG, Huijing PA et al. Clinical and molecular overlap between myopathies and inherited connective tissue diseases. Neuromuscul Disord 2008: 18: 843-856.
20. Behan WM, Longman C, Petty RK et al. Muscle fibrillin deficiency in Marfan's syndrome myopathy. J Neurol Neurosurg Psychiatry 2003: 74: 633-638.
21. Percheron G, Fayet G, Ningler T et al. Muscle strength and body composition in adult women with Marfan syndrome. Rheumatology (Oxford) 2007: 46: 957-962.
22. Cohn RD, van Erp C, Habashi JP et al. Angiotensin II type 1 receptor blockade attenuates TGF-beta-induced failure of muscle regeneration in multiple myopathic states. Nat Med 2007: 13: 204-210.
23. Neptune ER, Frischmeyer PA, Arking DE et al. Dysregulation of TGF-beta activation contributes to pathogenesis in Marfan syndrome. Nat Genet 2003: 33: 407-411.
24. Fattori R, Nienaber CA, Descovich B et al. Importance of dural ectasia in phenotypic assessment of Marfan's syndrome. Lancet 1999: 354: 910-913.
25. Foran JR, Pyeritz RE, Dietz HC, Sponseller PD. Characterization of the symptoms associated with dural ectasia in the Marfan patient. Am J Med Genet A 2005: 134: 58-65.
26. Di Lazzaro V, Pilato F, Dileone M et al. Extradural arachnoid cyst with lumbosacral cord and root compression in marfan syndrome. Arch Neurol 2007: 64: 284-285.
27. Hoshino Y, Edakuni H, Shimada H et al. Sacral arachnoid cyst associated with marfan syndrome. Intern Med 2005: 44: 271-273.
28. Sponseller PD, Shindle M. Orthopedic problems in Marfan syndrome. In: Robinson PN, Godfrey M, eds. Marfan syndrome: A primer for clinicians and scientists. New York: Kluwer Academic/Plenium Publishers, 2004: 24-34.
29. Nabors MW, Pait TG, Byrd EB et al. Updated assessment and current classification of spinal meningeal cysts. J Neurosurg 1988: 68: 366-377.
30. Voermans NC, van Alfen N, Pillen S et al. Neuromuscular involvement in various types of Ehlers-Danlos syndrome. Ann Neurol 2009 (in press).
31. Kendall FP, McCreary KE, Provance PG, Rodgers MM, Romani WA. Muscles testing and function with posture and pain. Baltimore, PA: Lippincott Williams & Wilkins, 2005.
32. van der Ploeg RJ, Fidler V, Oosterhuis HJ. Hand-held myometry: Reference values. J Neurol Neurosurg Psychiatry 1991: 54: 244-247.
33. Martina IS, van Koningsveld R, Schmitz PI, van der MechéFG, van Doorn PA. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. European Inflammatory Neuropathy Cause and Treatment (INCAT) group. J Neurol Neurosurg Psychiatry 1998: 65: 743-747.
34. Thompson R, Vignos P. Serum aldolase in muscle disease. AMA Arch Intern Med 1959: 103: 551-564.
35. Brooke MH, Griggs RC, Mendell JR, Fenichel GM, Shumate JB, Pellegrino RJ. Clinical trial in Duchenne dystrophy. I. The design of the protocol. Muscle Nerve 1981: 4: 186-197.
36. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor Assessment. Int Disabil Stud 1991: 13: 50-54.
37. Rankin J. Cerebral vascular accidents in patients over the age of 60. III. Diagnosis and treatment. Scott Med J 1957: 2: 254-268.
38. van Swieten JC, Koudstaal PJ, Visser MC, Schouten HJ, Van GJ. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988: 19: 604-607.
39. England JD, Gronseth GS, Franklin G et al. Distal symmetrical polyneuropathy: A definition for clinical research. A report of the American Academy of Neurology, the American Association of Electrodiagnostic Medicine, and the American Academy of Physical Medicine and Rehabilitation. Arch Phys Med Rehabil 2005: 86: 167-174.
40. Fuglsang-Frederiksen A. The role of different EMG methods in evaluating myopathy. Clin Neurophysiol 2006: 117: 1173-1189.
41. Pillen S, Arts IM, Zwarts MJ. Muscle ultrasound in neuromuscular disorders. Muscle Nerve 2008: 37: 679-693.
42. Scholten RR, Pillen S, Verrips A, Zwarts MJ. Quantitative ultrasonography of skeletal muscles in children: Normal values. Muscle Nerve 2003: 27: 693-698.
43. Pillen S, Verrips A, Van AN, Arts IM, Sie LT, Zwarts MJ. Quantitative skeletal muscle ultrasound: Diagnostic value in childhood neuromuscular disease. Neuromuscul Disord 2007: 17: 509-516.
44. Arts IM, Pillen S, Overeem S, Schelhaas HJ, Zwarts MJ. Rise and fall of skeletal muscle size over the entire life span. J Am Geriatr Soc 2007: 55: 1150-1152.
45. Weller B, Carpenter S, Lochmuller H, Karpati G. Myopathy with trabecular muscle fibers. Neuromuscul Disord 1999: 9: 208-214.
46. Gaist D, Jeppesen U, Andersen M, Garcia Rodriguez LA, Hallas J, Sindrup SH. Statins and risk of polyneuropathy: A case-control study. Neurology 2002: 58: 1333-1337.
47. Huijing PA. Epimuscular myofascial force transmission between antagonistic and synergistic muscles can explain movement limitation in spastic paresis. J Electromyogr Kinesiol 2007: 17: 708-724.
48. Voermans NC, Altenburg TM, Hamel BC, De HA, van Engelen BG. Reduced quantitative muscle function in tenascin-X deficient Ehlers-Danlos patients. Neuromuscul Disord 2007: 17: 597-602.
49. Isogai Z, Ono RN, Ushiro S et al. Latent transforming growth factor beta-binding protein 1 interacts with fibrillin and is a microfibril-associated protein. J Biol Chem 2003: 278: 2750-2757.
50. Charbonneau NL, Dzamba BJ, Ono RN et al. Fibrillins can co-assemble in fibrils, but fibrillin fibril composition displays cell-specific differences. J Biol Chem 2003: 278: 2740-2749.
51. Voermans NC, Drost G, Van KA et al. Recurrent neuropathy associated with Ehlers-Danlos syndrome. J Neurol 2006: 253: 670-671.
52. Camacho VO, Bertini E, Zhang RZ et al. Ullrich scleroatonic muscular dystrophy is caused by recessive mutations in collagen type VI. Proc Natl Acad Sci U S A 2001: 98: 7516-7521.
53. Jobsis GJ, Keizers H, Vreijling JP et al. Type VI collagen mutations in Bethlem myopathy, an autosomal dominant myopathy with contractures. Nat Genet 1996: 14: 113-115.